Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Jun Sik | - |
dc.contributor.author | Sohn, Won | - |
dc.contributor.author | Lee, Oh Young | - |
dc.contributor.author | Lee, Sang Pyo | - |
dc.contributor.author | Lee, Kang Nyeong | - |
dc.contributor.author | Jun, Dae Won | - |
dc.contributor.author | Lee, Hang Lak | - |
dc.contributor.author | Yoon, Byung Chul | - |
dc.contributor.author | Choi, Ho Soon | - |
dc.contributor.author | Chung, Won-Seok | - |
dc.contributor.author | Seo, Jae-Gu | - |
dc.date.accessioned | 2022-07-16T06:24:55Z | - |
dc.date.available | 2022-07-16T06:24:55Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2014-01 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/160888 | - |
dc.description.abstract | Background and AimThe efficacy of treatment with multispecies probiotics on irritable bowel syndrome (IBS) symptoms and the alterations of gut microbiota in patients who have taken probiotics were investigated. MethodsThis randomized, double-blind, placebo-controlled trial involved 49 IBS patients (probiotics: 25, placebo: 24) diagnosed according to the Rome III criteria. Patients were randomly assigned to two groups: either to receive multispecies probiotics (a mixture of Bifidobacterium longum, B.bifidum, B.lactis, Lactobacillus acidophilus, L.rhamnosus, and Streptococcus thermophilus) twice a day for 4 weeks or to receive a placebo twice a day for 4 weeks. The primary efficacy end-point was the proportion of participants whose IBS symptoms were substantially relieved at week 4. Secondary end-points were the intensity of abdominal pain/discomfort, bloating, stool frequency/consistency, alterations in fecal microflora over the 4 weeks. Fecal microflora were analyzed in 34 patients (probiotics: 17, placebo: 17) by quantitative real-time polymerase chain reaction assays. ResultsThe proportion of patients whose IBS symptoms were substantially relieved at week 4 was significantly higher in the probiotics group than in the placebo group: 68.0% (17/25) versus 37.5% (9/24) (P<0.05). Secondary end-points such as improvement in abdominal pain/discomfort and bloating occurred in the probiotics group but not in the placebo group. Fecal analysis revealed that B.lactis, L.rhamnosus, and S.thermophilus had increased significantly in the probiotics group after 4 weeks and that B.lactis had increased in the placebo group. ConclusionsMultispecies probiotics are effective in IBS patients and induce the alterations in the composition of intestinal microbiota. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Oh Young | - |
dc.contributor.affiliatedAuthor | Jun, Dae Won | - |
dc.contributor.affiliatedAuthor | Lee, Hang Lak | - |
dc.contributor.affiliatedAuthor | Yoon, Byung Chul | - |
dc.contributor.affiliatedAuthor | Choi, Ho Soon | - |
dc.identifier.doi | 10.1111/jgh.12322 | - |
dc.identifier.scopusid | 2-s2.0-84897584406 | - |
dc.identifier.wosid | 000328735600010 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, v.29, no.1, pp.52 - 59 | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.citation.title | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.citation.volume | 29 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 52 | - |
dc.citation.endPage | 59 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | 16S-23S RIBOSOMAL-RNA | - |
dc.subject.keywordPlus | LACTIC-ACID BACTERIA | - |
dc.subject.keywordPlus | REAL-TIME PCR | - |
dc.subject.keywordPlus | CLINICAL-TRIAL | - |
dc.subject.keywordPlus | INTESTINAL MICROBIOTA | - |
dc.subject.keywordPlus | RAPID IDENTIFICATION | - |
dc.subject.keywordPlus | TEMPORAL STABILITY | - |
dc.subject.keywordPlus | FECAL MICROBIOTA | - |
dc.subject.keywordPlus | GUT MICROBIOTA | - |
dc.subject.keywordPlus | SYMPTOMS | - |
dc.subject.keywordAuthor | irritable bowel syndrome | - |
dc.subject.keywordAuthor | microbiota | - |
dc.subject.keywordAuthor | probiotics | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/jgh.12322 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.